Tebipenem P Granules (Tebipenem) is the first oral carbapenem antibiotic and holds an important position in the treatment of pediatric respiratory tract infections. Its unique antibacterial spectrum covers drug-resistant Streptococcus pneumoniae and Haemophilus influenzae, providing a new option for anti-infective therapy in pediatrics.

What are the Precautions for Using Tebipenem P Granules (Tebipenem)?

Strictly Grasp Medication Indications

As a carbapenem antibiotic, this product must be used in strict accordance with the hierarchical management principles for antibacterial drugs.

It should only be considered when other antibacterial drugs are ineffective or inappropriate, to avoid abuse that may lead to the emergence of drug-resistant bacteria.

Bacterial culture and drug sensitivity tests should be performed prior to clinical use, and the drug should be selected rationally based on the test results.

Clarify Contraindicated Populations

It is absolutely contraindicated in patients with hypersensitivity to any component of this product.

Concomitant use with sodium valproate is contraindicated in patients taking sodium valproate, as it may cause a decrease in plasma concentrations of valproic acid and increase the risk of epilepsy recurrence.

It is also contraindicated in patients diagnosed with congenital metabolic abnormalities associated with carnitine deficiency.

Medication Considerations for Special Populations

Pregnant women: Use only when the therapeutic benefit outweighs the potential risk. The use of antibiotics containing pivoxil group in the late stage of pregnancy may lead to hypocarnitinemia in neonates.

Patients with renal insufficiency: For patients with moderate to severe renal insufficiency, drug excretion is delayed, so dosage adjustment is required and close monitoring of central nervous system symptoms is necessary.

Important Drug Interactions

In addition to the incompatibility with sodium valproate, concurrent use with H2-receptor antagonists or antacids may reduce the absorption rate of this drug.

Concomitant use with probenecid can inhibit renal excretion and increase plasma drug concentrations.

Monitoring During Administration of Tebipenem P Granules (Tebipenem)

Efficacy Monitoring Indicators

During treatment, closely observe the improvement of clinical symptoms such as body temperature, cough, and earache.

For patients with otitis media, otoscopic examinations are required to assess the degree of inflammation resolution.

For patients with pneumonia, monitor changes in signs such as respiratory rate and pulmonary rales.

The initial efficacy is usually evaluated 3 days after medication, and the course of treatment is completed within 7 days.

Metabolic System Monitoring

Focus on hypoglycemic symptoms related to hypocarnitinemia, especially in infant and young child patients.

Monitor for hypoglycemic precursors such as sweating, pallor, and palpitations; measure serum carnitine levels when necessary.

Allergic Reaction Monitoring

Closely observe for allergic manifestations such as skin rash, pruritus, and dyspnea in the early stage of medication.

Severe cases may develop life-threatening reactions such as shock and anaphylactic shock, which require immediate medical intervention.

Nervous System Monitoring

For patients with a history of epilepsy or central nervous system diseases, vigilance is required for adverse reactions such as convulsions and disturbance of consciousness.

Patients with renal insufficiency are at higher risk and should be under enhanced observation.

Digestive System Monitoring

Diarrhea and loose stools are the most common adverse reactions, with an incidence rate of approximately 19.5%.

Frequent diarrhea requires vigilance for pseudomembranous colitis; the drug should be discontinued promptly and corresponding measures should be taken.